Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/10/2025 | Overweight | Cantor Fitzgerald | |
12/2/2024 | $12.00 | Buy | Citigroup |
11/29/2024 | $7.00 → $11.00 | Outperform | Wedbush |
10/16/2024 | $15.00 | Outperform | Leerink Partners |
3/26/2024 | $22.00 | Buy | Guggenheim |
3/19/2024 | $30.00 | Buy | H.C. Wainwright |
3/7/2024 | $16.00 | Buy | Citigroup |
1/2/2024 | $14.00 | Equal Weight → Overweight | Wells Fargo |
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight
Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00
Wedbush resumed coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $11.00 from $7.00 previously
- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Emerging three-month non-human primate (NHP) data suggest that an alternate payload would be nec
LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025. A webcast of the presentation will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days. About Voyager TherapeuticsVoyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company dedicated to leveraging the power of human
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager's IV-delivered, CNS-penetrant TRACER capsids - LEXINGTON, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer's disease. The Company anticipates filing an investigational new drug (IND) application with the U.S. Food and Drug Administratio
144 - Voyager Therapeutics, Inc. (0001640266) (Subject)
144 - Voyager Therapeutics, Inc. (0001640266) (Subject)
SCHEDULE 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer's - - Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection - - INDs on track for three CNS gene therapies in 2025 in SOD1 ALS, GBA1 Parkinson's and other GBA1-mediated disease, and Friedreich's ataxia programs - LEXINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Thera
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - - Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate - - Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chief Financial Officer - - Strong cash position of $371 million as of June 30, 2024, expected to provide runway through multiple clinical data readouts into 2027 - LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology comp
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through